4. As of noon trading, Novo Nordisk A/S ( NVO) is down $0.42 (-1.1%) to $37.34 on light volume. Thus far, 255,964 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $37.21-$37.54 after having opened the day at $37.50 as compared to the previous trading day's close of $37.76. Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $87.1 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 2.2% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold. TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.